Indications for treatment

Except people with limited (< 12 months) life expectancy due to non-liver or non-HCV-related comorbidities, all those living with hepatitis C should be considered for treatment. This includes people with chronic hepatitis C, as well as all individuals with a risk factor for hepatitis C transmission who are found to have detectable HCV RNA in plasma or whole blood, regardless of the duration of infection. Urgent consideration for treatment should be given to those with advanced liver fibrosis or cirrhosis.